natgillin/translations-raw huggingface dataset:
The process of the disclosure can include a further step d) of purifying the virulence factor to produce a purified virulence factor. 
Fermentacijski postupak u skladu s patentnim zahtjevom 2, naznačen time što dodatno uključuje korak d) pročišćavanja čimbenika virulentnosti kako bi se dobilo pročišćeni čimbenik virulentnosti.
The method of paragraph 20, wherein the parasite are fleas or ticks. 
Mekani veterinarski pripravak za žvakanje za uporabu prema zahtjevu 33, naznačen time, da se kod parazita radi o buhama ili krpeljima.
A compound of claim 1 of formula IIC: or a pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, wherein: 
[image] Formula IIC ili njegova farmaceutski prihvatljiva sol, solvat, stereoizomer i/ili ester, pri čemu:
a lactose in an amount of about 16 mg; and 
(d) laktozu količinom od oko 16 mg; te
The boom mountable robotic arm of claim 1 wherein said at least one hinge includes a hinge plate having a fastener for securing said at least one hinge plate in an operating position in which said electrically insulated support posts extend perpendicularly away from said upper beam assembly. 
Robotska ruka koja se može montirati na krak dizalice prema zahtjevu 2, naznačena time, da navedena zglobna šarka uključuje zglobnu pločicu koja ima pričvršćivač za osiguranje navedenih barem jedne zglobne pločice u radnom položaju u kojem se navedeni električno izolirani podupirači protežu pod pravim kutom dalje od navedenog gornjeg grednog sklopa.
with one or more of the following modifications: 
Datum objave europskog patenta:
The system of claim 1, wherein at least one of the screws comprises a length that is between about 60 mm and about 90 mm. The system of claim 1, wherein the applicator guide comprises an end projection configured to engage with the recess of the nail and a longitudinal projection adapted to ensure placement of the nail at a desired angle in the calcaneus and insertion through the guide hole. A locking nail system for arthrodesis reconstruction of calcaneus fractures comprising: 
Sustav čavla sa zaključavanjem prema bilo kojem od zahtjeva 1 do 6, pri čemu dužina kalkaneus-talus vijaka (2) nije manja od 60 mm i nije veća od 90 mm. Sustav čavla sa zaključavanjem prema bilo kojem od zahtjeva 1 do 7, pri čemu isti dodatno obuhvaća jedan ili više sljedećih elemenata: svrdlo, mjerilo dubine, kanulirani odvijač, udarač, svrdlo s graničnikom i referentni zatik za vođenje.
hybridizing said target nucleic acid sequence to a second nucleic acid oligonucleotide comprising the nucleotide sequence of SEQ ID No 2 from nucleotide 1434 to nucleotide 1451 or its complement or said second nucleic acid oligonucleotide comprising the nucleotide sequence of SEQ ID No 3 from nucleotide 241 to nucleotide 258 or its complement, wherein said first and second oligonucleotide overlap by at least one nucleotide and wherein either said first or said second oligonucleotide is labeled to be said labeled nucleic acid probe; 
hibridiziranje navedene ciljne sekvence nukleinske kiseline na drugi oligonukleotid nukleinske kiseline koja sadrži nukleotidnu sekvencu iz SEQ ID No 2 od nukleotida 1434 do nukleotida 1451 ili njezin komplement ili navedeni drugi oligonukleotid nukleinske kiseline koja sadrži nukleotidnu sekvencu iz SEQ ID No 3 od nukleotida 241 do nukleotida 258 ili njezin komplement, pri čemu se navedeni prvi i drugi oligonukleotid preklapaju s barem jednim nukleotidom i pri čemu je bilo koji navedeni prvi ili navedeni drugi oligonukleotid označen da bude navedena označena proba nukleinske kiseline;
In some embodiments, step (c) further comprises filtering the reaction mixture to remove M1-R3 and provide a filtrate comprising the compound of formula (VIII). 
Postupak prema patentnom zahtjevu 38, gdje korak (c) dalje sadrži filtriranje reakcijske smjese da bi se dobio filtrat koji sadrži spoj formule (VIII).
The AC-AC HVDC converter system according to claim 1, wherein two first transformer functions of the at least one first transformer arrangement are integrated in the one physical transformer casing. 
Sustav pretvarača AC-AC HVDC prema zahtjevu 1, naznačen time što je dio dva prva sklopa transformatora od barem jednog prvog sklopa transformatora integriran u jednu fizičku transformatorsku jedinicu (730a-f; 830a-f;
Use of a compound according to claim 1 or a pharmaceutical composition according to claim 2 in the manufacture of a medicament for treating a disease and/or disorder of the eye. 
Spoj prema bilo kojem od zahtjeva 1-17 ili farmaceutski pripravak prema zahtjevu 18 naznačen time da je za uporabu za liječenje bolesti posredovane s JAK kinazom, odbacivanja transplantata alografta kod primatelja transplantata, autoimune bolesti posredovane T-stanicama ili bolesti i/ili poremećaja oka.
Granulation can occur spontaneously by the addition of water to the above described sugar replacement compositions. 
Granulacija se može zbivati spontano, dodavanjem vode gore opisanim sastavinama koje zamjenjuju šećer.
Example 4: Crystallization of batch C2 (monoclinic polymorph) 
Primjer 4: Kristalizacija serije C2 (monoklinski polimorf)
Amine salt of formula XII wherein R1 is benzyl, R3' is Boc and X is the anion of methanesulfonic acid. 
Sol amina formule XII naznačena time, da R1 je benzil, R3' je Boc, a X je anion metansulfonske kiseline.
In another aspect the invention provides a method for the prevention of the undesirable side effects associated with antipsychotic or antidepressant agents. 
Prema drugom aspektu, izum opisuje postupak za prevenciju nepoželjnih nuspojava povezanih s antipsihotičkim ili antidepresivnim agensima.
According to an embodiment, the organogelator comprises at least one unit of general formula (II): (R—NHCO)x—Z—(NHCO—R′)y 
Mješavina u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačena time što organogelator sadrži najmanje jednu jedinicu opće formule (II):
Evaluation of the Activity of the Compounds 
Datum objave europske prijave patenta:
Lighting unit according to claim 1 characterized in that said source unit (1) contains a number of panels (2) either separately or attached to each other in a releasable manner. 
Lampa prema zahtjevu 1 naznačena time što izvor (1) sadrži niz ploča (2) bilo odvojenih ili međusobno spojenih tako da se mogu i odvojiti.
An Fc-containing molecule according to claim 1, having decreased affinity for FcY receptors as compared to a wildtype Fc, comprising an antibody Fc domain based on an IgG2 constant region, wherein amino acid residues 233, 234, 235, 237, and 238 defined by the EU numbering system, comprise a sequence selected from PAAAP, PAAAS, and SAAAS and further comprising mutations H268A or H268Q, V309L, A330S and P331S as defined by the EU numbering system. 
14. Molekula koja sadrži Fc prema zahtjevu 1, koja ima smanjen afinitet za Fcy receptore u usporedbi sa Fc divljeg tipa, obuhvaćajući Fc domenu antitijela baziranu na IgG2 konstantnoj regiji, gdje aminokiselinski ostaci 233, 234, 235, 237, 1 238 definirani EU sistemom numeracije, sadrže sekvencu izabranu iz PAAAP, PAAAS i SAAAS 1 dalje obuhvaćajući mutacije H268A ili H268Q, V309L, A330S i P3315 kao što je definirano EU sistemom numeracije.
To evaluate in-vitro activity against HIV-integrase, 5 pmole of biotin labeled substrate DNA was bound to 100 ug of Streptavidin coated PVT SPA beads (Amersham Pharmacia Biotech). 
x 5 Biološki postupci Da bi se procijenilo in-vitro djelovanje protiv HIV-integraze, 5 pmola biotinom obilježene supstratne DNK je vezano za 100 ug streptavidinom obloženih PVT SPA granula (Amersham Pharmacia Biotech).
the monomers corresponding to Formula 11 constitute at least 85 wt.% based on the total weight of monomers of Formulae 11, 22, and 33 in the polymerization mixture and the weight ratio of monomers corresponding to Formula 22 to monomers corresponding to Formula 33 is from 4:1 to 1:4, or 
monomeri koji odgovaraju Formuli 11 sadrže najmanje 85 tež.% bazirano na ukupnoj težini monomera s Formulama 11, 22, i 33 u polimerizacijskoj mješavini i težinski udio monomera koji odgovaraju Formuli 22 prema monomerima koji odgovaraju Formuli 33 je od 4:1 do 1:4, ili
The guiding assembly of clause 1 wherein said the pitch angle of said fin is adjustable to values that are not lower than zero degrees and not higher than fifteen degrees. 
Sklop za navođenje u skladu s patentnim zahtjevom 1, naznačen time što navedeni kut nagiba navedenog krilca se može podesiti na vrijednosti koje nisu niže od nula stupnjeva i nisu više od petnaest stupnjeva.
in which R1 is a saturated or unsaturated, branched or linear radical having 9 to 19 carbon atoms, is applied to a substrate and this is optionally dried. 
CH,- OH gdje je R, zasićeni ili nezasićeni, razgranati ili linearni rađikal koji ima 9 do 19 atoma ugljika, manje od ili jednako 20% po masi vode.
The building of claim 7, wherein the covering layer includes a reinforcement layer, such as a woven mat, netting, mesh or the like, and preferably a fibre reinforced layer. 
Građevina prema zahtjevu 8, naznačena time da pokrovni sloj sadrži sloj za ojačanje, kao što je tkani mat, mreža od vlakana, plastična ili metalna mreža ili nešto slično i po mogućnosti vlaknima ojačani sloj.
Preferably, the mentioned materials being different from wood are metals or metal alloys, whereby here, in particular, aluminum or aluminum alloys have to be emphasized. 
Poželjno je da su navedeni materijali koji su različiti od drva metali ili legure metala, pri čemu se ovdje se trebaju naročito istaći aluminiji ili legure aluminija.
Preferably, Ar1 represents a Phenyl group optionally substituted, preferably substituted, by 1 up to 5 R group(s), wherein, each R, identical or different, is selected from the group consisting in Halogen atom, -Alkyl, -OAlkyl, 
Po mogućnosti, Arl predstavlja Fenilnu skupinu izborno supstituiranu, po mogućnosti supstituiranu, s 1 do 5 R skupina, gdje svakog R1, istog ili različitog, se bira iz skupine koju čine Halogeni atom, -Alkil, -OAlkil;
A method for recovering heat from wastewaters in a wastewater circuit, primary circuit and secondary circuit arranged in a heat transfer connection, comprising the steps of 
Postupak za oporabu topline iz otpadnih voda u kružnom sustavu otpadnih voda, primarni kružni tijek i sekundarni kružni tijek postavljeni su tako da čine priključak za prijenos topline koji je naznačen time da sadrži sljedeće korake:
The sartan for use according to claim 1, characterised in that the sartan is selected from the group consisting of: candesartan, eprosartan, irbesartan, losartan, tasosartan, telmisartan, valsartan, and a pharmaceutically acceptable salt thereof. 
Sartan za uporabu prema zahtjevu 1, naznačen time, da je sartan odabran iz skupine koju čine: kandesartan, eprosartan, irbesartan, losartan, tazosartan, telmisartan, valsartan i njihova farmaceutski prihvatljiva sol.
Use of at least one chemical entity according to any one of claims 1 and 3-8 for the manufacture of a medicament for antagonising the effects of oxytocin on the oxytocin receptor. 
Upotreba spoja, ili njegove farmaceutski prihvatljive adicijske soli s kiselinom, u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačena time što je spoj namijenjen proizvodnji medikamenta za antagoniziranje učinaka oksitocina na oksitocinskom receptoru.
clutch means for maintaining engagement between the first and second gear members in normal condition of the injection device, and for allowing disengagement of the first and second gear members upon a shock received by the injection device along the predetermined direction. 
sredstva sklopke (23, 25, 28) za održavanje zahvata između prvog i drugog elementa zupčanika (14, 13) u normalnom stanju injekcijskog uređaja, te za omogućavanje oslobađanja od prvog i drugog elementa zupčanika (14, 13) nakon primljenog šoka pomoću injekcijskog uređaja uzduž unaprijed određenog smjera (D), te navedena sredstva sklopke sadrže:
A heat source is placed inside an injection well. 
Izvor topline je postavljen unutar izvora injektiranja.
Pharmaceutical composition for use according to claim 12 or 13, whereas the pharmaceutical composition is administered intravenously. 
Farmaceutski pripravak namijenjen uporabi u skladu s patentnim zahtjevima 12 ii 13, naznačen time, da so farmaceutski pripravak daje intravenski.
The compound according to claim 1 or a pharmacologically acceptable salt thereof, wherein R1 represents a halogen atom. 
Spoj u skladu sa patentnim zahtjevom 1 ili 2 ili farmakološki prihvatljiva sol istog, gdje
The method according to claim 21, wherein the ternesite clinker and the Portland cement clinker are ground together or separately, with or without sulfate carriers in the form of alkali and/or alkaline earth sulfates to degrees of fineness (according to Blaine) ranging from 3000 to 6000 cm2/g. 
Postupak sukladno barem jednom od zahtjeva 1 do 8, naznačen time što je klinker samljeven do finoće (prema Blaineu) od 2000 do 10000 cm"/g poželjno od 3000 do 6000 cm'/g i poželjnije od 4000 do 5000 cm'/g sa ili bez nosača sulfata u obliku alkalijskih 1li1 zemnolakalijskih metala poželjno u obliku gipsa i/ili hemihidrata ili anhriodstata.
A method of treating a pathological condition associated with activation of c-met in a subject, said method comprising administering to the subject a substance that inhibits specific binding of HGF B chain to c-met, whereby c-met activation is inhibited. 
njihova kombinacija, pri čemu se tvar veže na aktivirani HGF B lanac i inhibira specifično vezanje spomenutog aktiviranog HGF B lanca na c-met, za liječenje patološkog stanja povezanog s aktivacijom c-met u pojedincu, pri čemu patološko stanje je rak, tumor, poremećaj proliferacije stanica, imunosni poremećaj ili poremećaj povezan s angiogenezom.
a sequence having at least 95 percent sequence identity to the full length of a DNA sequence selected from SEQ ID NOs:14, 15 and 17-20 and having gene regulatory activity, 
sekvence sa najmanje 95 posto identičnosti sekvence sa punom dužinom DNK sekvence odabrane od SEQ ID BR.:1-2 sa promotorskom aktivnosti,
The pharmaceutical composition for use according to claim 1, wherein delivery of the LIF preparation is by intracerebral implantation, intracerebroventricular (ICV) infusion, and/or convection enhanced diffusion (CED). 
Farmaceutski pripravak, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što pripravak s preparatom BMP-a unosi intracerebralnim usatkom, intracerebroventrikularnom (ICV) infuzijom i/ili konvekcijski poboljšanom difuzijom (CED).
Formulations of the invention that include compounds of Formula A or Formula B result in superior reduction in gene expression, as compared to formulations that do not include these compounds. Particularly surprising is the ability of formulations disclosed herein that include compounds of Formula A to reduce the expression of HSP47. In certain embodiments of the present disclosure, the retinoid is selected from the group consisting of vitamin A, retinoic acid, tretinoin, adapalene, 4-hydroxy(phenyl)retinamide (4-HPR), retinyl palmitate, retinal, saturated retinoic acid, and saturated, demethylated retinoic acid. 
Spoj za olakšavanje unošenja lijeka u ciljanu stanicu, koji sadrži strukturu (retinoid)m-veznik-(retinoid)n; pri čemu je retinoid izabran iz grupe koja sadrži vitamin A, retinsku kiselinu, tretinoin, adapalen, 4-hidroksi(fenil)retinamid (4-HPR), retinil palmitate, retinal, zasićenu retinsku kiselinu i zasićenu demetilirajuću kiselinu; pri čemu sum in neovisni 2 ili 3; 1 pri čemu je veznik izabran iz grupe koja sadrži bis-amido-PEG, tris -amido-PEG, tetra-amido-PEG, Lis-bis-amido-PEG-Lis, Lis-tris-amido-PEG-Lis, Lis-tetraamido-PEG-Lis, Lis-PEG-Lis, PEG2000, PEG1250, PEG1000, PEG750, PEG550 i PEG-Glu.
-(C3-C6)-cycloalkyl in which cycloalkyl is unsubstituted or substituted independently of one another once, twice or three times by R1, and Z is -(C1-C6)-alkyl, 
-(C3-C6)-cikloalkil, gdje cikloalkil nije supstituiran ili je međusobno neovisno mono-, di- ili trisupstituiran s R1, i Z je -(C1-C6)-alkil,
Ra2 is selected from hydrogen, C1-C6 alkyl optionally substituted with heterocyclyl, C1-C6 alkoxy, heterocycle, amino, amide, fluoro, and bromo; 
Ra, je odabran od sljedećih: vodik, Ci-C4 alkil, C;-Cg alkoksi, heterocikl, amino, amid, fluor i brom;
R′OH (III) in an organic solvent in the presence of a lipase from Candida to give cortexolone-17a-propionate, wherein R is CH3—CH2 and R′ is a linear aliphatic chain containing 1-10 carbon atoms and crystallizing said cortexolone-17a-propionate from a mixture of dichloromethane/n-hexane, or a mixture of acetone/n-hexane, or a mixture of ethanol/water, to give cortexolone-17a-propionate in crystalline form III. 
R'OH (II) u prisutnosti lipaze iz kvasca Candida, gdje je R CH3-CH., a R' je nerazgranati alifatski lanac s 1-10 atoma ugljika, kako bi se dobilo korteksolon-17a-propionat, te u kristaliziranju navedenog korteksolon-174-propionata iz terc- butil-metil-etera kako bi se dobilo korteksolon-17a-propionat u kristalnom obliku I.
The crude product was recrystallised from EtOH/water. 
Kruti produkt se rekristalizira iz EtOH/vode.
A method of increasing the stability of a protein in aqueous solution, said method comprising admixing said protein with a POE sorbitan, wherein said POE sorbitan increases the stability of said protein in the aqueous solution, wherein the aqueous solution is free of polysorbate, wherein the POE sorbitan is present at a concentration of from about 150 parts per million (ppm) to about 10,000 ppm, and wherein the aqueous solution does not comprise a microsphere. 
Postupak povećanja stabilnosti i/ili smanjenja agregacije proteina u vodenoj otopini, naznačen time, da spomenuti postupak obuhvaća miješanje spomenutog proteina s POE sorbitanom, pri čemu spomenuti POE sorbitan povećava stabilnost i/ili smanjuje agregaciju spomenutog proteina u vodenoj otopini; te time, da spomenuti postupak ostvaruje predmetni vodeni pripravak u skladu s patentnim zahtjevom 1.
The compound of claim 1 wherein the compound is of formula (VIb): 
Spoj patentnog zahtjeva 1 gdje spoj ima formulu (VIb):
It is usually given by mouth, the preferred route, in form of tablets or capsules, and has been given to children in the form of a suitable fruit juice, such as orange juice or as black currant or rose hip syrups. 
Obično se daje preko ustiju, što je put koji se preferira, u obliku tableta ili kapsula, te je davan djeci u obliku odgovarajućeg voćnog soka, kao što je sok od naranče ili sirupi od crnog ribizla ili šipka.
The components may be directly compressed, or may be granulated before compression. 
Sastojci mogu biti direktno komprimirani, ili mogu biti granulirani prije komprimiranja.
A method of treating or preventing a disease or disorder involving cells expressing CLD18, comprising administering to a subject an antibody of any one of claims 1 to 22, a conjugate of claim 25 or 26 or a pharmaceutical composition of claim 27. 
Antitijelo prema bilo kojem od patentnih zahtjeva 1 do 20, konjugat prema patentnom zahtjevu 22 ili farmaceutska kompozicija prema patentnom zahtjevu 23 za uporabu u postupku liječenja ili prevencije bolesti ili poremećaja koja/koji uključuje stanice koje eksprimiraju CLD18A2.
The method of claim 1, wherein said antigen or antigenic peptide of the second detector is from an organism selected from the group consisting of heartworm, Ehrlichia canis, Ehrlichia chaffeensis, Ehrlichia ewingii, Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, Anaplasma phagocytophilum, Anaplasma platys, feline leukemia virus, parvovirus, influenza A strain, influenza B strain, avian influenza virus, respiratory syncytial virus, Legionella, adenovirus, rotavirus, feline immunodeficiency virus, human immunodeficiency virus, and Group A Streptococcus. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeni antigen ili antigeni peptid izt drugog detektora je iz organizma kojeg se bira iz skupine koju čine srčana glista, Ehrlichia canis, Ehrlichia chaffeensis, Ehrlichia_ewingii, Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, Anaplazma phagocytophilum, Anaplazma platys, virus mačje leukemije, parvovirus, soj A influence, soj B influence, virus ptičje influence, respiratorni sincicijski virus, Legionella, adenovirus, rotavirus, virus mačje imunodeficijencije, virus ljudske imunodeficijencije, te skupina A streptokoka.
wherein R′″ represents hydrogen or —O—C1-6-alkyl, to obtain a compound of formula III 
O gdje R'"' predstavlja vodik ili -O-C, 4-alkil, radi dobivanja spoja formule III
The method of claim 4, wherein said first primer set contains a primer of at least 16 nucleotides in length that is located in SEQ ID NO:5 or SEQ ID NO:6 and a primer of at least 16 nucleotides in length that is located in SEQ ID NO:7. 
Postupak prema zahtjevu 4, pri čemu navedeni prvi set začetnica obuhvaća začetnicu od najmanje 16 u nizu poredanih nukleotida iz SEQ ID NO: 5 ili SEQ ID NO: 6, i začetnicu od najmanje 16 u nizu nukleotida, koji se nalaze u SEQ ID NO: 7.
In order to cope with non-response, psychiatrists sometimes make use of augmentation strategies. 
Kako bi doskočili nedostatku reakcije, psihijatri katkada pribjegavaju strategiji povećanja.
5% to 96.9% by weight, preferably 20% to 90% by weight, more preferably 30% to 80% by weight, of nylon-6 or nylon-6,6, 1% to 60% by weight, preferably 5% to 50% by weight, more preferably 10% to 40% by weight, of at least one quartz powder having a d95 of 5 to 250 um, preferably 10 to 150 um, more preferably 15 um to 90 um, and most preferably 16 to 55 um, 
Pripravci prema zahtjevu 1, naznačeni time što oni sadrže A) 5% do 96.9 težinskih % najlona-6 ili najlona-6,6, B) 1% do 60 težinskih % najmanje jednog kvarcnog praha koji ima d95 u rasponu od 5 do 250 um određeno laserskom difraktometrijom, C) 2% do 8 težinskih % usitnjenih dugih staklenih vlakana početne duljine u rasponu od 1 do 50 mm, i D) 00.1% do 40 težinskih % melamin cijanurata, uz uvjet da je zbroj svih težinskih postotaka uvijek 100.
The anti-CLDN 6 antibody of claim 1 which is capable of binding to CLDN6 associated with the surface of a cell that expresses CLDN6 and is not substantially capable of binding to CLDN9 associated with the surface of a cell that expresses CLDN9. 
Antitijelo suglasno zahtjevu 1, koje je sposobno da se veže za CLDN6 asociran na membrani stanice koja eksprimira CLDN6 i koje u biti nije sposobno da se veže za CLDN9.
A compound according to claim 3, wherein adjacent the cyclopropyl moiety is a double bond. 
Spoj prema zahtjevu 3, naznačen time da uz ciklopropilnu skupinu je dvostruka veza.
is hydrogen, substituted hydrocarbyl, or hydrocarbyl; 
je vodik, supstituirani hidrokarbil ili hidrokarbil:
an optional removable underlying liner; 
izbornu uklonjivu osnovnu oblogu;
The coupling reaction is suitably performed at −25° C. to 150° C., conveniently at ambient temperature. Process (l) By reacting a compound of Formula IV as defined above except that any functional group is protected if necessary, with a compound of the Formula V″: 
Postupak (1) Reakcija između spoja prikazanog Formulom TV u skladu sa gore navedenom definicijom, samo što je bilo koja funkcionalna skupina po potebi zaštićena, i spoja prikazanog Formulom V": m »- (CH koristeći postupak reduktivne aminacije.
Another embodiment of the present invention relates to a pharmaceutical composition comprising as active ingredient at least one of the derivatives of dianhydrohexite mononitrate according to formula (I), a tautomer, a pharmaceutically acceptable salt or a solvate thereof. 
Druga izvedba predloženog izuma odnosi se na farmaceutski sastav koji kao aktivan sastojak sadrži najmanje jedan derivat dianhidroheksit mononitrata prema formuli (I), njegov tautomer, farmaceutski prihvatljivu sol ili njegov solvat.
Dimensions, specifications, and characteristics can vary according to desire and need. 
Dimenzije, specifikacije 1 karakteristike mogu se mijenjati prema želji i potrebama.